Format

Send to

Choose Destination
See comment in PubMed Commons below
Tidsskr Nor Laegeforen. 2013 Oct 1;133(18):1940-5. doi: 10.4045/tidsskr.12.1111.

New oral anticoagulants--a review.

[Article in English, Norwegian]

Abstract

BACKGROUND:

Dabigatran, rivaroxaban and apixaban are three new oral anticoagulants that have recently been approved in Norway. The aim of this article is to provide an overview of the mechanisms of action, the most important indications and practical advice on the use of these drugs.

METHOD:

The review is based on published phase 3 studies, a literature search in PubMed and the authors' clinical experience.

RESULTS:

Indications for use of the new anticoagulants include thromboprophylaxis after total hip and knee replacement surgery (all three), prevention of stroke and systemic embolism in non-valvular atrial fibrillation (all three), treatment of acute venous thrombosis and secondary prophylaxis after venous thrombosis (currently only rivaroxaban). For the aforementioned indications, these drugs have proven to be non-inferior to standard established anticoagulation therapy. For atrial fibrillation, all three drugs have also shown a lower incidence of intracranial bleeding compared with standard treatment.

INTERPRETATION:

It is important to limit the use of these drugs to approved indications, to select patients who show good compliance, to rule out contraindications and to identify drug interactions. Monitoring of coagulation is not required, but patients should be followed up regularly to detect conditions that may lead to changes in the expected efficacy or safety.

Comment in

PMID:
24084970
DOI:
10.4045/tidsskr.12.1111
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Norwegian Medical Association
    Loading ...
    Support Center